Literature DB >> 9551686

Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-beta1 expression in pig serum-induced rat liver fibrosis in vivo.

I Sakaida1, K Uchida, Y Matsumura, K Okita.   

Abstract

BACKGROUND/AIM: The aim of this study was to investigate the effect of interferon gamma on the synthesis of matrix proteins such as collagens with the relation to transforming growth factor-beta1 expression in vivo.
METHODS: We investigated the effects of interferon gamma in a model of liver fibrosis induced by pig serum in male Wistar rats, which develops fibrosis without an increase in serum alanine aminotransferase (i.e., without hepatocyte injury). Rats were injected with 0.5 ml of pig serum twice a week for 8 weeks with or without 20,000 or 50,000 U of interferon gamma.
RESULTS: Interferon gamma at doses up to 50,000 U/day prevented fibrosis, as indicated by reduced hydroxyproline content in the liver. Interferon gamma at 50,000 U/day also reduced expression of type I and III procollagen in the liver. However, the expression of transforming growth factor-beta1 mRNA and protein in the liver was not reduced by interferon gamma. Histologically, interferon gamma at 50,000 U/day also reduced the number of myofibroblast-like cells (activated stellate cells).
CONCLUSIONS: These results indicate that interferon gamma can prevent fibrosis by inhibiting the activation and proliferation of stellate cells, resulting in reduced expression of procollagen without affecting transforming growth factor-beta1 expression in pig serum-induced rat liver fibrosis in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551686     DOI: 10.1016/s0168-8278(98)80322-x

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  10 in total

1.  Treatment of pig serum-induced rat liver fibrosis with Boschniakia rossica, oxymatrine and interferon-alpha.

Authors:  Chun-Song Wu; Xi-Xu Piao; Dong-Ming Piao; Yong-Ri Jin; Cheng-Hao Li
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

2.  Adeno-associated virus mediated interferon-gamma inhibits the progression of hepatic fibrosis in vitro and in vivo.

Authors:  Miao Chen; Guang-Ji Wang; Yong Diao; Rui-An Xu; Hai-Tang Xie; Xin-Yan Li; Jian-Guo Sun
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

3.  Distinctive role of Stat3 and Erk-1/2 activation in mediating interferon-gamma inhibition of TGF-beta1 action.

Authors:  Myrto Giannopoulou; Steven C Iszkula; Chunsun Dai; Xiaoyue Tan; Junwei Yang; George K Michalopoulos; Youhua Liu
Journal:  Am J Physiol Renal Physiol       Date:  2005-12-06

4.  Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient L-amino acid-defined diet in rats.

Authors:  I Sakaida; K Hironaka; K Uchida; K Okita
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

5.  Effect of natural interferon α on proliferation and apoptosis of hepatic stellate cells.

Authors:  Tomohiro Ogawa; Norifumi Kawada; Kazuo Ikeda
Journal:  Hepatol Int       Date:  2009-04-21       Impact factor: 6.047

6.  Loss of inhibitory growth regulation by TGF-beta1 in preneoplastic lesions in rat liver.

Authors:  I Sakaida; K Hironaka; K Uchida; K Okita
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

7.  Interferon-gamma inhibits adenosine A2A receptor function in hepatic stellate cells by STAT1-mediated repression of adenylyl cyclase.

Authors:  Eric T Block; Bruce N Cronstein
Journal:  Int J Interferon Cytokine Mediat Res       Date:  2010-10

8.  A novel small compound that promotes nuclear translocation of YB-1 ameliorates experimental hepatic fibrosis in mice.

Authors:  Kiyoshi Higashi; Yoshitaka Tomigahara; Hiroaki Shiraki; Kaori Miyata; Toshiyuki Mikami; Toru Kimura; Tadashi Moro; Yutaka Inagaki; Hideo Kaneko
Journal:  J Biol Chem       Date:  2010-11-28       Impact factor: 5.157

9.  T cell immune response is correlated with fibrosis and inflammatory activity in hepatitis B cirrhotics.

Authors:  Jie-Ting Tang; Jing-Yuan Fang; Wei-Qi Gu; En-Lin Li
Journal:  World J Gastroenterol       Date:  2006-05-21       Impact factor: 5.742

10.  PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling.

Authors:  Yuqing Liu; Eric Lik Hang Lui; Scott L Friedman; Lei Li; Tao Ye; Yongjun Chen; Ronnie T Poon; Jana Wo; Tsz Wai Kok; Sheung Tat Fan
Journal:  Lab Invest       Date:  2008-12-29       Impact factor: 5.662

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.